UBS Group
CTOR

UBS Group’s Citius Oncology CTOR Stock Holding History

UBS Group’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$218K Buy
334,619
+297,779
+808% +$237K ﹤0.01% 6740
2026
Q1 		$22.8K Buy
36,840
+15,376
+72% +$15.4K ﹤0.01% 7836
2025
Q4 		$21.5K Buy
21,464
+21,409
+38,925% +$30.7K ﹤0.01% 7735
2025
Q3 		$112 Sell
55
-15,368
-100% -$33.3K ﹤0.01% 9902
2025
Q2 		$67.1K Sell
15,423
-34,322
-69% -$40.1K ﹤0.01% 7540
2025
Q1 		$46.3K Buy
49,745
+24,940
+101% +$26.7K ﹤0.01% 7651
2024
Q4 		$28.5K Buy
24,805
+23,173
+1,420% +$26K ﹤0.01% 7641
2024
Q3 		$2.27K Buy
+1,632
New +$11.6K ﹤0.01% 8471
2023
Q2 		– Sell
-1,504
Closed -$15.6K – 9791
2023
Q1 		$15.6K Buy
1,504
+1,104
+276% +$11.3K ﹤0.01% 7285
2022
Q4 		$4.06K Buy
+400
New +$4.05K ﹤0.01% 9395

Other funds holding CTOR

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

UBS Group's CTOR Position: Q2 2026 in Review

UBS Group increased its Citius Oncology (CTOR) stake by 808% in Q2 2026, buying an estimated $237K and bringing the position to 334,619 shares worth $218K. The position accounts for ﹤0.01% of the portfolio, ranked #6740.

UBS Group first reported a position in CTOR in Q4 2022 and has held it in 10 quarters since. 19 funds tracked by Wall St. Rank hold CTOR as of Q2 2026.

  • UBS Group held 334,619 shares of Citius Oncology worth $218K as of Q2 2026.
  • UBS Group bought 297,779 Citius Oncology shares in Q2 2026, an estimated $237K.
  • Citius Oncology made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6740 holding.
  • UBS Group first reported a position in Citius Oncology in Q4 2022 and has held it in 10 quarters since.
  • 19 funds tracked by Wall St. Rank held Citius Oncology as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.